Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by MrMugsyon Dec 14, 2022 12:43am
308 Views
Post# 35170107

RE:RE:RE:RE:RE:RE:RE:RE:Upcoming ...

RE:RE:RE:RE:RE:RE:RE:RE:Upcoming ...
Benedictus wrote:

MrMugsy wrote:
woundedknee wrote: About time for Dan to sell some more of his shares. Christmas bills coming up. lol



Hahaha - I don't think it works that way but I could be wrong.

I think he covered some future capital gains on the sale of Antibe Holdings - but - maybe I'm wrong.  I would have done that myself.

Also - I'd be more concerned about unexpected sales like the one by Wallace out of nowhere.  The unknown and unexpected is a little harder to swallow.  Then again, to sell at lows is more preferred than selling at highs - I respect that part of Wallace's sale.

Going forward - don't think we'll see any selling from Dan/John as we head into P2 excitement.  Just my opinion.

Personally - I would have taken some of our cash and used it to buyback shares at this level - or at least threaten to do so.  It would have been the absolute wrong approach with our cash ... but I would have threatened it none-the-less.         : )

 

Mugs, I always appreciate your insights and optimism but a share buyback threat would have been an awful bluff and a tell of inept management.  They need every damn penny on hand and then some...and the market knows it.  I'm pleased they're just sticking to their knitting, don't need to dilute near term and moving everything forward. 2023 should be a better year for the longs and within 12 months, give or take, we will have successful acute p2 results. 



I agree Benedictus ... I'm just kidding.

By the end of 2022, we'll have $42.5 MM in the bank and we need a minimum of 2 years runway.
We also need cash on hand to pay for specialists as situations call for it.

I think we spent $2 MM on Liver Specialists.
We probably spent some money figuring out the amorphous solution.
I wouldn't doubt we spent money developing a superoxide scavenger already (Antiviral ?)
We're looking at an IV form of OTENA.
Figuring out if we need 352 in a head-to-head study now.
And ... who knows what wacky and wonderful things are coming in our IBD drug.

The cash is key for development work and it keeps us in the driver seat during OTENA negotiations.
<< Previous
Bullboard Posts
Next >>